about
The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone.Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex.Propofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a meta-analysis of randomized controlled trialsPrediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Use of sedative and analgesic agents in neurotrauma patients: effects on cerebral physiology.Interaction between erythromycin and nitrazepam in healthy volunteers.Dose of midazolam should be reduced during diltiazem and verapamil treatments.Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteersIs cyclosporin A an inhibitor of drug metabolism?The pharmacokinetics of midazolam following orthotopic liver transplantationIncreased volume of distribution prolongs midazolam half-life.The pharmacokinetics of midazolam in patients with congestive heart failure.Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady stateSedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis.Effect of midazolam on sleep.Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit.Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of actionMidazolam pharmacokinetics following intravenous and buccal administrationAbsolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.Oral sedation: a primer on anxiolysis for the adult patient.Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.Intranasal midazolam plasma concentration profile and its effect on anxiety associated with dental procedures.Arterial oxygen saturation in children receiving rectal midazolam as premedication for oral surgical proceduresCardiac dysrhythmias with midazolam sedation.Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions.Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Sedation in traumatic brain injury.Alternative delivery systems for agents to treat acute agitation: progress to date.Sedation for fibreoptic bronchoscopy.An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method.Does midazolam sedation in oral surgery affect the potency or duration of diflunisal analgesia?Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.Pharmacokinetics and pharmacodynamics in the critically ill patient.Recovery following sedation with midazolam or diazepam alone or in combination with fentanyl for outpatient surgery.A comparison of transcutaneous PO2 in patients sedated with diazepam-fentanyl or midazolam-fentanylPharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis.
P2860
Q24538601-6FEE4BFF-FFA2-4407-AA77-D38140A652A9Q24538958-D399A1E4-FA01-4636-874A-41E2933B7192Q28543189-621B89C2-2B64-478A-84F8-F23831CF6979Q31044030-941E0AB4-082F-481E-8EA1-8EB7BD6A6B6CQ34230318-7EF2A34E-CD66-473E-8378-CC3AA24BC8CCQ34300475-029D1FDF-DA0A-4610-AFA6-B96AE61EE389Q34346089-27A7769F-B343-4CF6-AF7F-7A8A78EFAE48Q34347427-3DB5F01D-DF1A-4454-A22D-2B4B4F8FCF10Q34357736-DDB59F45-8A7B-4E6E-903C-C619F1126D0AQ34397693-A0EF6F8D-E243-497D-A3EF-21604D84AA21Q34398254-7F6620D7-7F02-49CC-B427-8EA633707F16Q34398445-6CC1F5A4-DA0C-4578-815C-8C3A1DBE683EQ34417679-F660C096-87F8-45A2-B5F7-836B627D6049Q34448235-3C759568-E0AB-4E19-A11B-006D977F5BF5Q34513565-FF9D7DCE-0444-4328-B2BC-C7F341D3ADCDQ34552609-43A07766-130E-4EBD-ACC4-9DE67B407F38Q34686236-CC7CE385-3328-4957-9224-50C7994DA2B7Q34810573-031B7A1E-7DDA-4F7B-B341-EE0E2134D34AQ35113271-6E090FD8-1F14-4BDD-90F3-979D7C70D55CQ35802566-70E5D95D-EAD6-40AC-9EC1-CBFC36DB417DQ35804041-6B5F354E-A5FF-417F-B86B-1FFABF55419BQ36012601-C94A0360-5CF3-4AF9-BC50-293E44E3FA11Q36055339-906EFE86-1BDB-4839-988B-04C2EEB761D7Q36289723-32633845-A165-4099-8EFD-DA3D4698D9CAQ36308866-E4F394BE-8088-444C-A57D-B0622F638BCBQ36309622-8BA8DE9D-6C11-49A9-B28D-EF9601A1006FQ37135750-B07A8359-ADE9-4608-9D79-342C4174E013Q37733572-859004CE-55A0-4A56-BB65-0389BD2FB844Q38040844-7CBEB099-90D4-4856-BE42-CBDF46A3E2E0Q38050783-0B1C1AD1-F0E8-4F18-A71E-655E12DE1519Q38154852-6EEFB779-DFA7-48F3-920B-32BC2171B1F6Q38735582-E8754180-D67B-4741-9A2C-211E5AFDBACAQ39226311-CF1360A9-688D-486E-93BC-E61978B18657Q39515701-26B40391-52FF-4F67-9D65-77E144D1FAD5Q39767125-F8B90C8F-7204-4AE2-A024-0B1404D028C4Q40801223-868B59BC-1C88-476D-9702-CE9C87C1BC58Q40815584-744B76A4-3C61-4CF3-9187-76CBE5EAA261Q41774121-FAA8F79B-854F-4387-8CD1-723E317D7766Q41853354-30B858B2-B78F-475A-94B6-4AC72FBFC159Q41858171-665ACF9E-E122-4F4E-8261-9645CB030CB6
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
Midazolam kinetics.
@en
Midazolam kinetics.
@nl
type
label
Midazolam kinetics.
@en
Midazolam kinetics.
@nl
prefLabel
Midazolam kinetics.
@en
Midazolam kinetics.
@nl
P2093
P356
P1476
Midazolam kinetics.
@en
P2093
P304
P356
10.1038/CLPT.1981.217
P407
P577
1981-11-01T00:00:00Z